

BLOOD STORAGE LESIONS AND OTHER BIOCHEMICAL CHANGES ASSOCIATED WITH DONOR BLOOD

^{1*}Obeagu Emmanuel Ifeanyi, ²Okoroiwu, I.L.

¹Diagnostic Laboratory Unit, University Health Services Department, Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria.

²Department of Medical Laboratory Science, Imo State University, Owerri.

Article Received on
26 Feb 2015,

Revised on 17 March 2015,
Accepted on 09 April 2015

***Correspondence for
Author**

**Obeagu Emmanuel
Ifeanyi**

Diagnostic Laboratory
Unit, University Health
Services, Michael Okpara
University of Agriculture,
Umudike, Abia State,

ABSTARCT

This paper reviewed lesions and some biochemical changes associated with stored Packed red blood cell in transfusion medicine. There are some biochemical changes and lesions that develop in stored blood. There is a decrease in 2,3-DPG levels in stored blood which maintain the integrity of red blood cell. There is also gradual decrease in ATP level which affect every energy-dependent process which the cell may want to conduct. The absence of ATP results in dysfunction of ion pumps and other membrane proteins, which in turn results in all sorts of impaired mechanisms, most notably the maintenance of red blood cell shape. There is change from normal shape of red blood cell to abnormal shape. There is haemolysis and release of free haemoglobin. There is also accumulation of metabolic byproducts and

proinflammatory molecules. Packed red blood cell should be transfused young irrespective of the anticoagulants. The viability of the transfused cells should be ensured for general well-being of the patient.

KEYWORDS: Lesions, 2,3-DPG, ATP, Ion pumps, Membrane proteins, Free haemoglobin.

STORAGE LESIONS AND OTHER BIOCHEMICAL CHANGES ASSOCIATED WITH DONOR BLOOD


This paper discusses the changes which develop in packed red blood cells as a result of being stored in the refrigerator.

The longevity of packed red blood cells

Blood has a use-by date. In Australia, packed red blood cells can only be stored for a maximum of 42 days (which is slightly conservative - internationally, the maximum PRBC shelf life is 49 days). These storage maximums were arrived at completely arbitrarily.

Changes in red blood cells during storage

During the golden age of physiology, when scientists wore hats and white lab coats, a series of articles was published which addressed the problems of packed red blood cell storage in exquisite detail.



The ageing of red blood cells is a complicated topic. It is possible to summarise it by dividing the process by affected variables, rather than by arbitrary time stages. Time stages would also work - some lesions occur earlier, and others later. As the above graph suggests, these changes begin their evolution immediately as the blood is sucked out by the phlebotomist; however *clinically relevant* storage lesions only appear after a few days of refrigeration.

Sudden decrease in 2,3-DPG levels

The normal value for intracellular 2,3-DPG for an erythrocyte is around 4.5 mmol/L. After 24 hours of refrigeration, this value drops to about 3.0-3.5 mmol/L, and the entire 2,3-DPG supply is depleted after two weeks. This has dire consequences for the oxygen-carrying capacity of these cells. 2,3-DPG is an allosteric modulator of oxy-haemoglobin binding; its absence exhibits itself as a greatly increased oxygen affinity for any given partial pressure of O₂ (a massive left shift of the dissociation curve).

The disadvantage of this is the utter functional uselessness of such transfused blood. Certainly, it might appear to carry oxygen, but it will not let go of it once it is in the tissues. This persists *in vivo*, well after the transfusion has completed - even after 8 hours 2,3-DPG levels are only 33% of their normal value.

Does this have a clinically relevant effect? perhaps not. Only one (rodent-themed) study has demonstrated a decrease in oxygenation when one uses older cells. The decrease in totally 2,3-DPG depleted cells was in the order of 15%. This finding could not be replicated, confirming that the oxygen carrying capacity of normoxic organisms is probably not affected. This makes a certain amount of sense. The top of the oxyhemoglobin concentration curve really does not move- only the middle and bottom. Given that there is an *increased* capacity for oxygen binding, one would expect that overall oxygen carrying capacity is not impaired. Rather, oxygen extraction is impaired. Thus, if one's patient had a circulating volume composed entirely of recently thawed PRBCs, their whole body oxygen extraction would be less than 25%, and their venous saturation would be high.

Gradual decrease in ATP levels

The levels of ATP within RBCs tend to drop slowly, and diminish to insanely low levels by the end of 5 weeks. Understandably, this has implications for pretty much every energy-dependent process which the cell may want to conduct. The absence of ATP promotes the dysfunction of ion pumps and other membrane proteins, which in turn results in all sorts of impaired cellular mechanisms, most notably the maintenance of RBC shape (which is a surprisingly active process).

Red cell shape and rheology

As membrane proteins are damaged and lost, and as ion pumps begin to fail, so the starving erythrocytes begin to swell and to take on a more spherical or hemispherical appearance. Then, they shapeshift into monstrous spherocytocytes, with numerous non-deformable protrusions of cellular membrane sticking out in all directions. . Several studies of red cell morphology following cold storage have concluded that this failure of normal shape decreases the deformability of erythrocytes, and thus decreases flow through the microvasculature.

Microcirculatory changes in response to the transfusion of stored red blood cells. The rheological handicap of stored spherocytocytes may slow the capillary flow enough to

generate a clinically significant deficit of systemic oxygen delivery, which might be felt most in those tissues which are hungriest. Brain and kidney come to mind.

Red cell membrane vesiculation

This phenomenon is the consequence of transmembrane protein failure, and leads to an increased inflammatory response to the red cells. Such cells are also more osmotically fragile, and (with the loss of membrane elasticity) are even less deformable. They will not find it easy to slip through the microcirculation. Furthermore, such abnormal-looking cells will not survive the passage through the reticuloendothelial system. Haemolysis may ensue.

Haemolysis and the release of free hemoglobin

The destruction of RBCs both in the bag of cells and in the patient's bloodstream leads to the dispersion of free haemoglobin throughout the circulation. This has certain consequences beyond the development of a mild hyperbilirubinaemia. Free hemoglobin is actually an excellent nitric oxide scavenger. This reaction is treated briefly in the section on metabolism and clearance, inside the drug monograph on inhaled NO. To summarise, excess free haemoglobin results in the loss of nitric oxide, and thus in a reversal of normal mechanisms of NO-associated hypoxic vasodilation in poorly perfused organs. The result is vasoconstriction; essentially the opposite of what happens in vasoplegic shock. In the absence of NO-mediated bloodflow autoregulation, hypoxic tissues may be unable to attract a diversion of bloodflow, and shock will persist.

Accumulation of metabolic byproducts

Though not strictly speaking a change of the red blood cells themselves, the waste products of their metabolism which accumulate in the bag are noxious enough to cause serious problems. For instance, one can readily identify a source of trouble in the massive amount of potassium and lactate which is sloshing around in the extremely acidic environment of the 42-day-old blood bag. One might be tempted to conclude that hyperkalemia and lactic acidosis may result from a transfusion of too many units of old blood, but it does not seem to happen very often. A Mayo Clinic retrospective case series, spanning a term between 1988 and 2006, had unearthed only 16 cases of hyperkalemic cardiac arrest associated with PRBC transfusion. Compared to the total numbers of patients who had undergone blood transfusion at the Mayo Clinic over that time, this complication must be rare indeed - comparable to the risk of contracting HIV from the blood.

Accumulation of proinflammatory molecules

The process of slowly being pickled in your own wastes leads one to the intuitive conclusion that some of the changes will fill the environment with proinflammatory products of decay. The notion that packed red cell transfusion triggers an inflammatory response has been confirmed within the limitations of a murine model. It appears the inflammatory response requires membrane-encapsulated RBC haem, rather than the free haemoglobin which inevitably forms. Furthermore, it seems that the transfusion of RBCs induces an acute phase response, and exacerbates inflammation induced by endotoxin. The free iron which is released after haemoglobin lysis ends up in the circulation, and this has the effect of sponsoring bacterial growth.

Of course, sceptics might point out that mice and mouse blood are not effective experimental surrogates for human blood transfusion research. This can be countered by the observations of investigators such as Guillermo A. Escobar's group, who in 2007 confirmed that stored PRBC transfusions seem to upregulate proinflammatory gene expression in the leukocytes of the transfusion recipient. The in-vivo inflammatory effects of transfusion were confirmed by McFaul *et al*, who in 2009 found that human packed red cell suspensions stored in standard solutions become increasingly proinflammatory as a function of storage time. The culprits seem to be lipid fragments which have been shed from disintegrating membranes of the hideously deformed stored red cells- we know this because the acellular products do not seem to have this effect. The immunoactivating effects of these lipid fragments have been recognised for some time - here is a 1997 study linking these "neutrophil-priming agents" to the pathogenesis of transfusion-associated acute lung injury (TRALI).

The practice of using the oldest packed cells

There has for some time existed a common bloodbanking policy of using the oldest red blood cells on the shelf, in view of the fact that they were about to expire. In this fashion, stock was preserved.

Of course, this does not mean that all the PRBC units you ever get are at the borders of expiry. The mean age of transfused cells worldwide is about 16-21 days. A good article published by several luminaries of Australian ICU medicine discusses this practice and its consequences. The authors lament that *"most clinical studies in this area have been observational in nature, retrospective in design, small in size, and subject to bias, leaving this issue unresolved for more than 20 years."*

The argument for the use of "young" packed cells in ICU

Critically ill patients may be more susceptible to these storage lesions than the average punter. For instance, let's take TRALI. There is a good reason to believe on a theoretical basis- that the neutrophil-activating properties of the abovementioned broken lipid fragments can lead to a "second hit" in an already injured lung, rendering it even leakier, and filling it with oedema fluid to the ongoing frustration of the intensivist. This is merely one argument - consider that ICU patients have many more transfusions than other patients, that ICU patients have higher circulating proinflammatory cytokine levels already, etc etc. Lastly, the microvascular underperfusion which results from the use of stored cells is a major disadvantage to ICU patients who already have a uselessly defective microcirculation.

REFERENCES

1. Goodnough, Lawrence T., Jerrold H. Levy, and Michael F. Murphy. "Concepts of blood transfusion in adults." *The Lancet*, 2013; 381.9880: 1845-1854.
2. Spahn, Donat R., and Lawrence T. Goodnough. "Alternatives to blood transfusion." *The Lancet*, 2013; 381.9880: 1855-1865.
3. There is also a rescinded document from the NHMRC (2001) which has been used to guide practice: Clinical Practice Guidelines on the Use of Blood Components.
4. To some extent this document has been superseded by the Australian and New Zealand Society of Blood Transfusion GUIDELINES FOR THE ADMINISTRATION OF BLOOD PRODUCTS.
5. The Patient Blood Management Guidelines from the National Blood Authority of Australia is another series of documents worth looking at - it contains several important modules which have been reviewed and which act as successors to the 2001 NHMRC guidelines.
6. Treleaven, Jennie, et al. "Guidelines on the use of irradiated blood components prepared by the British Committee for Standards in Haematology blood transfusion task force." *British Journal of Haematology*, 2011; 152.1: 35-51.
7. Aoun, Elie, et al. "Transfusion-associated GVHD: 10 years' experience at the American University of Beirut—Medical Center." *Transfusion*, 2003; 43.12: 1672-1676.
8. Heddle, Nancy M., and Morris A. Blajchman. "The leukodepletion of cellular blood products in the prevention of HLA-alloimmunization and refractoriness to allogeneic platelet transfusions [editorial]." *Blood*, 1995; 85.3: 603-606.

9. Sharma, R. R., and Neelam Marwaha. "Leukoreduced blood components: Advantages and strategies for its implementation in developing countries." *Asian journal of transfusion science*, 2010; 4.1: 3.
10. Dzik, Walter H. "Leukoreduction of blood components." *Current opinion in hematology*, 2002; 9.6: 521-526.
11. Corwin, Howard L., and James P. AuBuchon. "Is leukoreduction of blood components for everyone?." *JAMA*, 2003; 289.15: 1993-1995.
12. Blajchman, M. A. "The clinical benefits of the leukoreduction of blood products." *Journal of Trauma-Injury, Infection, and Critical Care*, 2006; 60.6: S83-S90.
13. Rosenbaum, Lizabeth, et al. "The reintroduction of nonleukoreduced blood: would patients and clinicians agree?." *Transfusion*, 2011; 51.12: 2739-2743.
14. Bilgin, Y. M., L. M. van de Watering, and A. Brand. "Clinical effects of leucoreduction of blood transfusions." *Neth J Med*, 2011; 69.10: 441-450.
15. Australian Red Cross - Blood Service Policy on "The Age of Red Cells"
16. Hess, John R. "Red cell changes during storage." *Transfusion and Apheresis Science*, 2010; 43.1: 51-59.
17. Bennett-Guerrero, Elliott, et al. "Evolution of adverse changes in stored RBCs." *Proceedings of the National Academy of Sciences*, 2007; 104.43: 17063-17068.
18. Gabrio, Beverly Wescott, et al. "Erythrocyte preservation. I. The relation of the storage lesion to in vivo erythrocyte senescence." *Journal of Clinical Investigation*, 1954; 33.2: 242.
19. Gabrio, Beverly Wescott, Alexander R. Stevens Jr, and Clement A. Finch. "Erythrocyte preservation. II. A study of extra-erythrocyte factors in the storage of blood in acid-citrate-dextrose." *Journal of Clinical Investigation*, 1954; 33.2: 247.
20. Gabrio, Beverly Wescott, Alexander R. Stevens Jr, and Clement A. Finch. "Erythrocyte preservation. III. The reversibility of the storage lesion." *Journal of Clinical Investigation*, 1954; 33.2: 252.
21. Gabrio, Beverly Wescott, et al. "ERYTHROCYTE PRESERVATION IV. IN VITRO REVERSIBILITY OF THE STORAGE LESION." *Journal of Biological Chemistry*, 1955; 215.1: 357-367.
22. Gabrio, Beverly Wescott, D. M. Donohue, and C. A. Finch. "Erythrocyte preservation. V. Relationship between chemical changes and viability of stored blood treated with adenosine." *Journal of Clinical Investigation*, 1955; 34.10: 1509.

23. Donohue, Dennis M., Clement A. Finch, and Beverly Wescott Gabrio. "Erythrocyte preservation. VI. The storage of blood with purine nucleosides." *Journal of Clinical Investigation*, 1956; 35.5: 562.
24. Gabrio, Beverly Wescott, et al. "Erythrocyte preservation. VII. Acid-citrate-dextrose-inosine (ACDI) as a preservative for blood during storage at 4 C." *Journal of Clinical Investigation*, 1956; 35.6: 657.
25. Kor, Daryl J., Camille M. Van Buskirk, and Ognjen Gajic. "Red blood cell storage lesion." *Bosn J Basic Med Sci*, 2009; 9(1): 21-27.
26. Beutler, E., A. Meul, and L. A. Wood. "Depletion and Regeneration of 2, 3-diphosphoglyceric Acid in Stored Red Blood Cells." *Transfusion*, 1969; 9.3: 109-114.
27. Henkelman, Sandra, et al. "Is red blood cell rheology preserved during routine blood bank storage?." *Transfusion*, 2010; 50.4: 941-948.
28. Hardeman, M. R., and C. Ince. "Clinical potential of in vitro measured red cell deformability, a myth?." *Clinical hemorheology and microcirculation*, 1999; 21.3: 277-284.
29. d'Almeida, Mark S., et al. "Effect of prophylactic transfusion of stored RBCs on oxygen reserve in response to acute isovolemic hemorrhage in a rodent model." *Transfusion*, 2001; 41.7: 950-956.
30. Berezina, Tamara L., et al. "Influence of storage on red blood cell rheological properties." *Journal of surgical research*, 2002; 102.1: 6-12.
31. Wagner, G. M., et al. "Spectrin oxidation correlates with membrane vesiculation in stored RBCs." *Blood*, 1987; 69.6: 1777-1781.
32. Steck, Theodore L., and John Yu. "Selective solubilization of proteins from red blood cell membranes by protein perturbants." *Journal of supramolecular structure*, 1973; 1.3: 220-232.
33. Almac, Emre, and Can Ince. "The impact of storage on red cell function in blood transfusion." *Best Practice & Research Clinical Anaesthesiology*, 2007; 21.2: 195-208.
34. Donadee, Chenell, et al. "Nitric oxide scavenging by red blood cell microparticles and cell-free hemoglobin as a mechanism for the red cell storage lesion." *Circulation*, 2011; 124.4: 465-476.
35. Wolfe, L. C. "The membrane and the lesions of storage in preserved red cells." *Transfusion*, 1985; 25.3: 185-203.
36. Smith, Hugh M., et al. "Cardiac arrests associated with hyperkalemia during red blood cell transfusion: a case series." *Anesthesia & Analgesia*, 2008; 106.4: 1062-1069.

37. Twomley, Katie M., Sunil V. Rao, and Richard C. Becker. "Proinflammatory, immunomodulating, and prothrombotic properties of anemia and red blood cell transfusions." *Journal of thrombosis and thrombolysis*, 2006; 21.2: 167-174.
38. Hod, Eldad A., et al. "Transfusion of red blood cells after prolonged storage produces harmful effects that are mediated by iron and inflammation." *Blood*, 2010; 115.21: 4284-4292.
39. McFaul, Steve J., et al. "Packed blood cells stored in AS-5 become proinflammatory during storage." *Transfusion.*, 2009; 49.7: 1451-1460.
40. Escobar, Guillermo A., et al. "Stored packed red blood cell transfusion up-regulates inflammatory gene expression in circulating leukocytes." *Annals of surgery*, 2007; 246.1: 129.
41. Silliman, Christopher C., et al. "Partial characterization of lipids that develop during the routine storage of blood and prime the neutrophil NADPH oxidase." *The Journal of laboratory and clinical medicine*, 1994; 124.5: 684-694.
42. Silliman, Christopher C., et al. "The association of biologically active lipids with the development of transfusion-related acute lung injury: a retrospective study." *Transfusion.*, 1997; 37.7: 719-726.
43. Vincent, Jean Louis, et al. "Anemia and blood transfusion in critically ill patients." *Jama.*, 2002; 288.12: 1499-1507.
44. Tsai, Amy G., Pedro Cabrales, and Marcos Intaglietta. "Microvascular perfusion upon exchange transfusion with stored red blood cells in normovolemic anemic conditions." *Transfusion.*, 2004; 44.11: 1626-1634.